Taysha Gene Therapies, Inc. $TSHA Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 178.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,176,742 shares of the company’s stock after buying an additional 1,395,268 shares during the period. SG Americas Securities LLC owned 0.76% of Taysha Gene Therapies worth $9,730,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vestal Point Capital LP increased its position in shares of Taysha Gene Therapies by 150.0% in the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after acquiring an additional 8,250,000 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth about $11,178,000. Barclays PLC grew its stake in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at about $20,471,000. Finally, State Street Corp increased its holdings in shares of Taysha Gene Therapies by 49.1% in the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TSHA. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Bank of America upped their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Chardan Capital reissued a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Citizens Jmp lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 23rd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $12.38.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $6.34 on Friday. The stock has a market cap of $1.82 billion, a PE ratio of -16.68 and a beta of 1.19. The business has a 50-day simple moving average of $6.11 and a 200-day simple moving average of $5.29. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 52-week low of $2.25 and a 52-week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.